Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuyi Hu

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|February 8, 2022
The impact of awareness and attitudes towards long-action reversible contraceptives on the intention to use: a survey among youth with unintended pregnanciesHainan Chen, Heqing Song, Mu Li, et al.
Tissue & Cell|May 11, 2026
Ablation of ASF1B mitigates the proliferation of A549 cells and enhances anti-PD-L1 therapy by regulating ferroptosisJiamin Shi, Ying Fang, Shuyi Hu, et al.
Contrast Media & Molecular Imaging|July 14, 2022
Radiomics Analysis on Noncontrast CT for Distinguishing Hepatic Hemangioma (HH) and Hepatocellular Carcinoma (HCC)Shuyi Hu, Xiajie Lyu, Weifeng Li, et al.
Journal of Gastrointestinal Oncology|January 16, 2025
The potential role of tumor deposits in the prognosis and TNM staging for colorectal cancerXinhong Shi, Lin Lu, Zihan Wang, et al.
Cancer Biology & Medicine|December 10, 2025
Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapyShuyi Hu, Zipeng Wu, Yingying Dai, et al.
Translational Lung Cancer Research|July 11, 2026
Prognostic analysis and beneficiary population exploration of subsequent treatment regimens after third-generation EGFR-TKIs failure in EGFR-mutated advanced non-small cell lung cancer: a retrospective cohort studyZipeng Wu, Tianyi Liu, Ruofan Yu, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|September 17, 2025
Polymeric micellar paclitaxel, cisplatin, and tislelizumab as first-line therapy for advanced unresectable esophageal squamous cell carcinoma: A phase II study with resistance profiling in poor respondersCaolu Liu, Zipeng Wu, Yingying Dai, et al.
Clinical and Translational Medicine|June 19, 2025
Long-term survival and association of neoadjuvant chemotherapy with or without immunotherapy in resectable esophageal squamous cell carcinomaLin Lu, Lei Xia, Xinhong Shi, et al.
Frontiers in Oncology|April 12, 2024
Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature reviewYuxin Ma, Xinhong Shi, Kun Zhao, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception|February 8, 2022
The impact of awareness and attitudes towards long-action reversible contraceptives on the intention to use: a survey among youth with unintended pregnanciesHainan Chen, Heqing Song, Mu Li, et al.
Tissue & Cell|May 11, 2026
Ablation of ASF1B mitigates the proliferation of A549 cells and enhances anti-PD-L1 therapy by regulating ferroptosisJiamin Shi, Ying Fang, Shuyi Hu, et al.
Contrast Media & Molecular Imaging|July 14, 2022
Radiomics Analysis on Noncontrast CT for Distinguishing Hepatic Hemangioma (HH) and Hepatocellular Carcinoma (HCC)Shuyi Hu, Xiajie Lyu, Weifeng Li, et al.
Journal of Gastrointestinal Oncology|January 16, 2025
The potential role of tumor deposits in the prognosis and TNM staging for colorectal cancerXinhong Shi, Lin Lu, Zihan Wang, et al.
Cancer Biology & Medicine|December 10, 2025
Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapyShuyi Hu, Zipeng Wu, Yingying Dai, et al.
Translational Lung Cancer Research|July 11, 2026
Prognostic analysis and beneficiary population exploration of subsequent treatment regimens after third-generation EGFR-TKIs failure in EGFR-mutated advanced non-small cell lung cancer: a retrospective cohort studyZipeng Wu, Tianyi Liu, Ruofan Yu, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|September 17, 2025
Polymeric micellar paclitaxel, cisplatin, and tislelizumab as first-line therapy for advanced unresectable esophageal squamous cell carcinoma: A phase II study with resistance profiling in poor respondersCaolu Liu, Zipeng Wu, Yingying Dai, et al.
Clinical and Translational Medicine|June 19, 2025
Long-term survival and association of neoadjuvant chemotherapy with or without immunotherapy in resectable esophageal squamous cell carcinomaLin Lu, Lei Xia, Xinhong Shi, et al.
Frontiers in Oncology|April 12, 2024
Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature reviewYuxin Ma, Xinhong Shi, Kun Zhao, et al.
Pageof 2